Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion
of the global population, both physically and mentally. Current evidence suggests that the …
of the global population, both physically and mentally. Current evidence suggests that the …
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …
approved (or emergency authorized) in the US or globally, including remdesivir …
[HTML][HTML] Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme
The COVID-19 pandemic, driven by the novel coronavirus SARS-CoV-2, has drastically
reshaped global health and socioeconomic landscapes. The papain-like protease (PLpro) …
reshaped global health and socioeconomic landscapes. The papain-like protease (PLpro) …
In silico and in vitro inhibition of host-based viral entry targets and cytokine storm in COVID-19 by ginsenoside compound K
SARS-CoV-2 is a novel coronavirus that emerged as an epidemic, causing a respiratory
disease with multiple severe symptoms and deadly consequences. ACE-2 and TMPRSS2 …
disease with multiple severe symptoms and deadly consequences. ACE-2 and TMPRSS2 …
Identification of a novel inhibitor of SARS‐CoV‐2 main protease: an in silico, biochemical, and cell‐based approach
The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid
emergence of novel variants, and concerns over the effectiveness of existing vaccines …
emergence of novel variants, and concerns over the effectiveness of existing vaccines …
Targeting proteases involved in the viral replication of SARS-CoV-2 by sesquiterpene lactones from chicory (Cichorium intybus L.)
MÁ Ávila-Gálvez, C Rafael-Pita, N Fernández… - Food & Function, 2022 - pubs.rsc.org
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus causing a respiratory
disease that emerged in 2019, leading to a public health emergency situation which …
disease that emerged in 2019, leading to a public health emergency situation which …
Native mass spectrometry reveals binding interactions of SARS-CoV-2 PLpro with inhibitors and cellular targets
VK James, RN Godula, JM Perez… - ACS Infectious …, 2024 - ACS Publications
Here we used native mass spectrometry (native MS) to probe a SARS-CoV protease, PLpro,
which plays critical roles in coronavirus disease by affecting viral protein production and …
which plays critical roles in coronavirus disease by affecting viral protein production and …
Can Duvelisib and Eganelisib work for both cancer and COVID-19? Molecular-level insights from MD simulations and enhanced samplings
SARS-CoV-2 has caused severe illness and anxiety worldwide, evolving into more dreadful
variants capable of evading the host's immunity. Cytokine storms, led by PI3Kγ, are common …
variants capable of evading the host's immunity. Cytokine storms, led by PI3Kγ, are common …
Computational Assessment of Clinical Drugs against SARS‐CoV‐2: Foreseeing Molecular Mechanisms and Potent Mpro Inhibitors
The emergence of new SARS‐CoV‐2 variants of concern (VOC) is a propulsion for
accelerated potential therapeutic discovery. SARS‐CoV‐2's main protease (Mpro), essential …
accelerated potential therapeutic discovery. SARS‐CoV‐2's main protease (Mpro), essential …
[HTML][HTML] Recent developments in the therapeutics of SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmittable
respiratory virus that causes COVID-19 disease. Since its emergence in the early 2000s …
respiratory virus that causes COVID-19 disease. Since its emergence in the early 2000s …